Defining the cell kinetics basis for these differences in SCF stability could lead to effective solutions for the problem of loss of mesenchymal stem cell (MSC) function when MTC preparations are expanded for research and clinical applications. Here, KITLG is linked to medullary thyroid gland carcinoma.